SNRIs and norepinephrine reuptake inhibitors

SNRIs are high-yield second-generation antidepressant monographs across FRANZCP, MRCPsych and ABPN. Examiners want dose-dependent dual action, agent-level starts and ceilings, blood-pressure monitoring, discontinuation (especially venlafaxine), duloxetine pain and hepatic niches, and the reboxetine evidence-integrity story — not a brand list or the claim that every SNRI is automatically “stronger than every SSRI.” This leaf topic deepens the antidepressant hub for dual and noradrenergic reuptake drugs.[3][5][11][19]

Definition and classification

An SNRI (serotonin–norepinephrine reuptake inhibitor) inhibits the serotonin transporter (SERT) and the norepinephrine transporter (NET). A selective NRI inhibits NET with minimal SERT effect at clinical doses — clinically important because reboxetine (depression) and atomoxetine (ADHD) are not interchangeable with venlafaxine or duloxetine in exam answers.[1][11][12]

Mechanisms — the viva core

Venlafaxine occupancy teaching point. In healthy-volunteer and clinical physiological studies, lower doses of venlafaxine produce predominantly serotonergic reuptake inhibition, while higher doses recruit noradrenergic reuptake inhibition — Blier and colleagues quantified dose-related effects on SERT and NET function, and Debonnel and colleagues showed differential physiological effects of low versus high doses in major depression.[1][2] Exam translation: starting venlafaxine XR 75 mg is not automatically a “full dual-action” regimen; noradrenergic contribution and BP risk rise as you climb toward 150–225 mg (and specialist higher doses where used).[1][13]

Desvenlafaxine. O-desmethylvenlafaxine is venlafaxine’s major active metabolite; it inhibits both SERT and NET and is typically used at a simpler fixed oral dose (commonly 50 mg daily in outpatients) with placebo-controlled MDD efficacy data at 50 and 100 mg/day ranges.[10]

Duloxetine. Dual SERT/NET inhibition at usual antidepressant doses with RCT support at 60 mg once daily for MDD and broader programme data for painful physical symptoms; pain benefit should not be reduced to “it only works if mood improves” without examining the analgesia literature, but examiners also punish claiming a pure opioid-free panacea.[7][8][9]

Reboxetine. Selective NET inhibition made it the textbook “pure NRI antidepressant.” The 2010 systematic review including unpublished data concluded overall ineffectiveness and potential harm relative to placebo/SSRIs, with published evidence distorted by publication bias — this is an evidence-literacy exam favourite, not an optional history footnote.[11]

Atomoxetine. Selective NET inhibitor with once-daily RCT efficacy in children and adolescents with ADHD; clinical onset is measured in weeks, unlike stimulants. Full ADHD prescribing detail lives in the stimulants topic; here it anchors the NRI class map.[12]

Epidemiology and risk context

SNRIs are widely prescribed for MDD, anxiety disorders and selected pain syndromes. Fellowship risk language focuses on dose-related BP elevation (venlafaxine meta-analysis of thousands of trial patients), discontinuation symptoms with short half-life agents, hyponatraemia (shared SSRI/SNRI association), sexual dysfunction, and rare but catastrophic serotonin toxicity when combined with MAOIs or stacked serotonergics.[13][14][15][16][18]

When to choose an SNRI

RANZCP mood-disorder guidance and CANMAT pharmacological sections place dual-reuptake agents within stepped antidepressant care: first-line options for many adults with moderate–severe MDD include several SSRIs and SNRIs (and other first-line agents) based on prior response, comorbidity, tolerability priorities and local formulary — not a single mandatory brand.[19][20]

Common fellowship selection triggers for SNRI over another first-line class:

• Prior good response to an SNRI or SSRI nonresponse where a cross-class switch is planned (STAR*D switch arm included venlafaxine-XR).[4]
• Comorbid GAD with venlafaxine XR trial evidence in nondepressed outpatients over six months.[6]
• Depressive syndrome with clinically important painful physical symptoms or licensed neuropathic/fibromyalgia indications where duloxetine (or milnacipran where available) is rational.[7][9]
• Need for an agent with different sexual or activation profile after shared decision — still discuss Montejo-level sexual dysfunction risk honestly for serotonergic SNRIs.[16]

Do not choose an SNRI to “force dual action at 37.5 mg,” to treat bipolar I depression as if it were unipolar MDD, or to avoid monitoring. Baseline bipolar screen, suicide risk review and BP remain non-negotiable.[19][13]

Agent-level doses (adult oral exam frameworks)

Ranges are orientation anchors for exams and guidelines teaching. Always check current product information, renal/hepatic labels, and local PBS/authority rules; start lower in older adults and medically frail patients.[19][20]

Landmark evidence every candidate must own

Dose pharmacology. Blier 2007 and Debonnel 2007 are the mechanism pair for “when is venlafaxine dual?” — cite them rather than inventing receptor affinities from memory.[1][2]

Venlafaxine versus SSRIs. Thase’s pooled remission analysis reported higher remission with venlafaxine than SSRIs as a class — historically used to claim SNRI superiority. Cipriani’s 2018 network meta-analysis of 21 antidepressants places efficacy–acceptability differences in a broader, more modest comparative frame: use Thase as history-of-ideas, Cipriani as modern ranking humility, and STAR*D as sequential-care reality.[3][5]

STAR*D Level 2 switch. After citalopram failure, switching to bupropion-SR, sertraline or venlafaxine-XR produced broadly similar remission rates — choose by comorbidity and tolerability, not mythology that venlafaxine is mandatory after every SSRI failure.[4]

Duloxetine programme. Detke and Goldstein RCTs established antidepressant efficacy; Perahia and related analyses address painful symptoms — know both mood and pain exam stems.[7][8][9]

Reboxetine / Eyding. Including unpublished trials overturned the published efficacy narrative — examiners use this to test critical appraisal, not only pharmacology.[11]

Selection algorithm and monitoring

Before first dose (document): unipolar vs bipolar/mixed screen; suicide risk and means; sexual function baseline; concurrent serotonergics (tramadol, triptans, St John’s wort, MAOI history); pregnancy potential; BP and HR; U&E with sodium especially in older adults; LFTs when duloxetine planned or hepatic risk present; alcohol use.[13][15][19][20]

Early follow-up: days to 2 weeks for nausea, activation, akathisia, insomnia and suicidality (especially under 25 and after dose increases); BP after each substantial venlafaxine/desvenlafaxine increase; then efficacy and tolerability at 2–4–6 weeks.[19][14]

Maintenance. Continuation after response reduces relapse risk for antidepressants as a class (Geddes-level teaching lives in the antidepressant hub); plan duration by episode number and residual symptoms, and taper rather than stop cold — especially venlafaxine.[14][19]

Adverse effects and emergencies

Blood pressure

Thase’s meta-analysis of original data from 3744 depressed patients is the classic citation for venlafaxine’s blood-pressure effects — clinically, expect dose-related risk of sustained diastolic elevation in a minority and always recheck BP when escalating.[13]

Discontinuation syndrome

Consensus recommendations describe a common, usually time-limited syndrome after abrupt stop or missed doses, worse with short half-life serotonergic agents — venlafaxine is examiners’ favourite SNRI example. Educate at initiation; taper on cessation; distinguish from true depressive relapse that needs separate planning.[14]

Sexual dysfunction and hyponatraemia

Montejo’s prospective multicentre cohort showed high rates of treatment-emergent sexual dysfunction across many antidepressants including dual agents — discuss before prescribing. Movig’s case-control study links antidepressant use with hyponatraemia; SNRI use in older adults demands sodium vigilance like SSRIs.[16][15]

Serotonin toxicity

Clinical diagnosis on the continuum of neuromuscular excitation, autonomic hyperactivity and altered mental status. Apply Hunter Serotonin Toxicity Criteria when a serotonergic agent is present (spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor with hyperreflexia; hypertonia with temperature above 38°C plus ocular or inducible clonus — use the published decision tree precisely).[17][18]

Management: stop serotonergic agents; ABC support; benzodiazepines for agitation; cooling; specialist consideration of cyproheptadine; ICU for severe hyperthermia/rigidity. Never combine irreversible MAOIs with SNRIs; respect washouts (commonly about 2 weeks from most SNRIs to MAOI; longer after fluoxetine if switching the other direction from SSRI pathways).[18][19]

Duloxetine hepatic and other agent-specific issues

Product warnings and clinical teaching emphasise caution or avoidance in substantial hepatic disease and heavy alcohol use; stop for jaundice or significant enzyme rises. Sweating, dry mouth, nausea (early), constipation, and urinary hesitation/retention are noradrenergic-serotonergic mechanism-linked complaints, not mysteries.[7][20]

Switching, augmentation pointers and scenarios

From SSRI to SNRI: cross-taper or direct switch depending on dose, half-life and patient stability; watch for serotonergic overlap symptoms during cross-taper. STAR*D supports venlafaxine-XR as one legitimate switch after SSRI failure, not the only one.[4][14]

Partial response: optimise dose (remember venlafaxine dual-action dose band), confirm adherence, then augment (lithium, atypical antipsychotic, T3) or switch using antidepressant-hub logic — do not stack random serotonergics.[19][20]

Pain-depression overlap: duloxetine 60 mg once daily (titrate as tolerated toward labelled maxima up to 120 mg) is the standard fellowship example; document pain targets separately from mood scores.[7][9]

Anxiety disorders: venlafaxine XR has randomised evidence in GAD without comorbid depression over six months — still use stepped psychological care where indicated.[6]

ADHD NRI path: atomoxetine is the selective NRI for ADHD when stimulants fail, are refused, or diversion risk is high — multi-week trial, BP/HR monitoring (see stimulants topic).[12]

Special populations

Older adults. Start low (e.g. venlafaxine XR 37.5 mg); hyponatraemia and falls; BP; drug interactions; avoid assuming “SNRI is safer than SSRI” for sodium.[15][13]

Youth. Class antidepressant suicidality signal requires close early review; SNRI first-line status is more restricted than in adults in many paediatric pathways — prefer specialist frameworks.[19]

Pregnancy and lactation. Individualised risk–benefit with perinatal psychiatry/obstetrics; untreated depression harms mother and fetus; do not stop abruptly without a plan (discontinuation plus relapse risk).[19]

Hepatic and renal impairment. Duloxetine hepatic caution is high-yield; several SNRIs need renal dose adjustment per label — check product information rather than memorising every eGFR band incorrectly.[20]

Hypertension. Control BP before aggressive venlafaxine titration; choose alternative agents when BP is labile or monitoring will fail.[13]

Prognosis and disposition

Target remission, not mere response; residual symptoms drive relapse. After nonresponse to an optimised SNRI trial, switch or augment using measurement-based care and step up to TRD pathways (including lithium/atypical antipsychotic augmentation or ECT/esketamine interfaces) when severity or risk outstrips outpatient titration speed.[4][5][19]

Evidence, guidelines and controversies

Controversies to handle calmly: how large the true venlafaxine-versus-SSRI remission advantage is; whether higher venlafaxine doses are worth BP and side-effect costs; reboxetine’s residual niche if any; industry influence on dual-action branding. Answer with dose, monitoring and patient values — not slogans.[3][5][11]

Exam pearls

References

1. [1]Blier P, Saint-André E, Hébert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers Int J Neuropsychopharmacol, 2007.PMID 16690005
2. [2]Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression Int J Neuropsychopharmacol, 2007.PMID 16690006
3. [3]Thase ME, Entsuah AR, Rudolph RL Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br J Psychiatry, 2001.PMID 11230034
4. [4]Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med, 2006.PMID 16554525
5. [5]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
6. [6]Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial JAMA, 2000.PMID 10865302
7. [7]Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial J Clin Psychiatry, 2002.PMID 12000204
8. [8]Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial J Clin Psychiatry, 2002.PMID 11926722
9. [9]Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol, 2006.PMID 17012978
10. [10]Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder Curr Med Res Opin, 2008.PMID 18507895
11. [11]Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials BMJ, 2010.PMID 20940209
12. [12]Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry, 2002.PMID 12411225
13. [13]Thase ME Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients J Clin Psychiatry, 1998.PMID 9818630
14. [14]Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research J Clin Psychiatry, 2006.PMID 16683860
15. [15]Movig KL, Leufkens HG, Lenderink AW, et al. Association between antidepressant drug use and hyponatraemia: a case-control study Br J Clin Pharmacol, 2002.PMID 11966666
16. [16]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
17. [17]Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM, 2003.PMID 12925718
18. [18]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664
19. [19]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
20. [20]Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments Can J Psychiatry, 2016.PMID 27486148